Key facts
- Notable investors include US National Science Foundation, Virginia Innovation Partnership Corporation.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for AxonDx
- ·The full record, as it builds
Funding rounds
No funding rounds for AxonDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AxonDx
Developer of a circulating tumor cells detection device designed to scan all nucleated cells in a blood sample. The company's device scans un-enriched blood samples in minutes, finds all classes of circulating tumor cells shed by solid tumors, and offers a morphological and outsourced molecular characterization of positive cells, enabling cancer patients to self-diagnose early-stage cancer.
- Sector
- Healthcare
- HQ
- Earlysville, VA, United States
- Founded
- 2013
- Website
- axondx.com/
- Ownership
- Privately Held (backing)
AxonDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AxonDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AxonDx in its N-PORT filings yet. We sweep new filings monthly.